×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
LIXTE Biotechnology Holdings Provides Update on Recent Activities
GlobeNewswire
Publishing of Findings in Recent Pre-Clinical Study for LIXTE's Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation...
5 days ago
Lixte Biotechnology provides update on recent activities - TipRanks.com
Tipranks
LIXTE Biotechnology Holdings provided an update on the Company's recent activities, including notable pre-clinical developments.
5 days ago
Lixte CEO Takes On a New Course
Los Angeles Business Journal
Pasadena-based pharmaceutical company Lixte Biotechnology Holdings Inc.'s new chief executive is also charting a new course for the company...
3 months ago
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER ...
Yahoo Finance
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE...
1 month ago
Why Lixte Biotechnology Stock Is Soaring - Lixte Biotechnology (NASDAQ:LIXT)
Benzinga
Lixte Biotechnology Holdings, Inc. LIXT shares are trading higher Wednesday after the company announced the publication of pre-clinical data...
1 month ago
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
GlobeNewswire
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber...
2 weeks ago
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy ...
Yahoo Finance
Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE)...
2 months ago
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
GlobeNewswire
The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially...
2 months ago
Why Is Lixte Biotech (LIXT) Stock Down 29% Today?
InvestorPlace
Why Is Lixte Biotech (LIXT) Stock Down 29% Today? · Lixte Biotech (LIXT) stock is falling after a rally yesterday. · That came alongside news of...
15 months ago
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Yahoo Finance
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology Holdings...
7 months ago